Michael Goldberg, PhDDana-Farber Cancer Institute2014 Kirwin-Hinton Family Scholar Unraveling the role of ATR in DNA repair and ovarian cancer therapy The majority of cancer therapies attempt to kill tumor cells using drugs that are often toxic. Many patients relapse because residual cells can establish new drug-resistant tumors. Unlike traditional therapies, the immune system can adapt […]
Read MoreStarting April 1, 2025, the Rivkin Center’s ovarian cancer research funding, global symposium and fundraising activities will continue under the leadership of Ovarian Cancer Research Alliance (OCRA).
